In experimental models of portal hypertension, a number of receptor tyrosine kinase inhibitors, including imatinib, sunitinib and sorafenib, have been shown to regulate splanchnic neovascularization and improve portal hypertension [6], [7]. Here, NTRK1 is linked to liver disorder.